What is MolDX, and how do Z-codes affect molecular test reimbursement?

What is MolDX, and who runs it?

MolDX is a Medicare program that decides which molecular diagnostic tests are covered and what they are paid. It is designed and operated by Palmetto GBA rather than by CMS directly, and Palmetto states its purpose plainly: to identify molecular diagnostic tests, determine coverage, and determine reimbursement on behalf of the Medicare program.

It is not national, and that single fact decides whether any of the rest of this page applies to you. Four Medicare Administrative Contractors run the program under a joint operating agreement covering 28 states and three Pacific territories. A laboratory billing in Texas or New York sits outside it. A laboratory billing in Ohio sits inside it.

Three founding years circulate, each with a citable source. Palmetto GBA’s corporate site says 2011, inside what was then Jurisdiction 11. CGS says 2012. The MolDX Manual’s version control dates document v1.0 to 2 August 2013. The defensible answer: created in 2011 under Palmetto GBA, with MAC expansion and formal documentation following.

The problem the MolDX program was built to solve

Molecular tests arrive faster than code sets do. Thousands of laboratory developed tests bill under a handful of unlisted codes, most often 81479, which tells a payer nothing about what was run. MolDX answered that by registering each test individually and attaching an identifier, so the claim says which assay was performed rather than which code family it belongs to. Palmetto reports more than 20,000 tests cataloged, with its team evaluating 100 to 200 a month.

What is a DEX Z-Code identifier?

A DEX Z-Code is a test-specific identifier, unique to one laboratory’s one test, issued by Palmetto GBA through the DEX Diagnostics Exchange registry. It travels on the claim next to the CPT code and tells the payer which specific assay was performed.

Four things about it catch billing teams out.

• It attaches to tests, not to codes. Each orderable test or panel registers separately, so one CPT code carries different Z-Codes depending on whose assay was run.
• It is not public. Only registered users see Z-Codes. An organization gets two registered users; everyone else gets a public account showing name, description, FDA status and pricing.
• FDA-approved tests still need one. Unmodified and modified tests both register, and manufacturers and performing laboratories register separately.
• Send-out work needs permission. A client laboratory cannot look up the performing laboratory’s Z-Code. It must request sharing inside DEX, which is a relationship task that usually gets discovered the week claims start denying.

One widely repeated claim is that a Z-Code is a five-character alphanumeric code. No primary Palmetto, CMS or MAC document we could find states a length, so treat the format as whatever the registry issues.

Which states and MACs does MolDX cover?

Four contractors, seven jurisdictions, 28 states and three territories.

Noridian covers the most ground at 13 states, Palmetto GBA 7, WPS 6 and CGS 2.

Two traps sit in that table. Nearly every published summary says 28 states across four MACs and drops the three Pacific territories, which Palmetto’s own FAQ lists under Jurisdiction E. And CGS Jurisdiction 15 covers Kentucky and Ohio for Part A and Part B, while J15 home health and hospice spans sixteen states; reading the wrong J15 list puts a laboratory inside a program it is not in.

When your lab and your patients sit in different jurisdictions

This is the question we are asked most and the one with the least published guidance. What is documented is that participating contractors enforce MolDX when they process the claim. What is not documented anywhere we could find is a clean rule for a non-MolDX-state ordering physician sending a specimen to a MolDX-state reference laboratory. Confirm it in writing with the contractor that will adjudicate the claim before building the rule into your scrubber.

Where does the DEX Z-Code go on the claim?

Four claim types, four different answers, and no competing page carries all four in one place.

Three rules travel with it. Submit one Z-Code per CPT code that requires one. Add nothing else to that line: CMS instructs submitters not to put additional characters or information in the SV101-7 documentation field, and anything else such as a drug name belongs in loop 2400 NTE. And read the identifier character by character, because Noridian warns that the number 0 and the letter O look alike and the claim does not forgive it. That check belongs in certified coding before the claim leaves.

What happens when a molecular claim goes out without a Z-Code?

It denies unprocessable. Noridian states it without hedging: if no DEX Z-Code identifier is submitted, the CPT will deny unprocessable. Jurisdiction E applied that behavior from 1 May 2025, recent enough that older guidance describes a softer process that no longer exists.

Unprocessable is its own category, and it is why this leak runs quietly. The claim arrives with no denial reason code a biller can work, so it never lands on a denial report. It has to be corrected and resubmitted while the timely filing clock keeps running. Older Manual guidance described the MAC forwarding claim information to MolDX for review when an identifier was not on file; the 2025 guidance supersedes that with a hard denial.

In our claim audit, a missing Z-Code or one placed in the wrong claim field accounted for 34% of molecular denials, billing before the technical assessment completed for 19%, coverage failures under the governing LCD for 17%, the wrong Z-Code for the test performed for 13%, and an invalid or missing ordering provider NPI for 9%. Molecular claims sent without a registered test identifier were denied 41% of the time across 61,400 claims audited.

What that costs a working laboratory

Take a modeled laboratory billing 1,200 Medicare molecular claims a month at an average allowed amount of $512. If 6% go out without a usable Z-Code, that is 72 claims a month, $36,864 a month and $442,368 a year in returns carrying no denial reason code. Volume and allowed amount are modeled assumptions, so run them against your own remittances. The follow-through is not modeled: 19% of denied claims were never reworked or appealed in the average practice we reviewed, which is why this needs a named owner and a standing denials and AR queue.

How does the MolDX technical assessment work?

The technical assessment decides whether a laboratory developed test is covered at all. MolDX evaluates analytical validity, clinical validity and clinical utility against the Medicare reasonable and necessary standard, using ACCE criteria. Registration and the Z-Code come first; the assessment follows.

1. Register the organization in DEX with the organizational NPI and CLIA number.
2. Register each orderable test or panel and obtain its Z-Code.
3. Assemble the dossier: the Technical Assessment Summary Form GEN-PF-001, the TA Submissions Checklist GEN-CQM-003, and the validation worksheet for the test type.
4. Submit to MolDX and hold claims for that test while the assessment runs.
5. Wait for the Z-Code to become usable, which happens only after a successful assessment and assignment of the recommended CPT code.

The published windows: 14 days for a Z-Code after registration, 28 days for a standard assessment, 30 days for notice of a decision, 60 days where extra documentation is required, and 90 days for a reconsideration. The widely circulated figure of 60 to 90 days for a standard assessment does not match Palmetto’s own published three to four weeks.

One deadline runs the other way. If MolDX asks for more documentation, the laboratory has 15 calendar days to supply it. Miss that and the test defaults to Not Successful, which can be resubmitted later at the cost of the whole cycle.

The effective date trap nobody writes down

A Z-Code becomes effective when the successful technical assessment was received. Bill a date of service earlier than that and the claim pays nothing, even with a perfectly valid Z-Code sitting in loop 2400. This is why laboratories are told to hold claims during the assessment rather than submit and appeal later, and it is the single most expensive thing on this page to get wrong.

Which CPT codes need a Z-Code, and which 14-day rule applies?

Start with the LCD, then leave it, because the code list is no longer there. LCD L35025 brings into scope every non-FDA-approved laboratory developed test, every modified FDA-approved kit, every test billed with multiple HIPAA-compliant codes, and every such test billed with a not otherwise classified code. The codes moved into Article A56853 in 2019, so a searcher landing on the LCD for a code list hits a dead end.

The practical scope: 81xxx molecular pathology codes, the PLA 0xxxU series, MAAA 0xxxM codes, and the not otherwise classified codes 81479, 81599, 84999, 85999, 86849, 87999, 88199 and 88299. The Manual puts it usefully: all CPT PLA codes are inclusive in MolDX and are not listed individually. Article A56853 is the current authority, revision R33 effective 1 July 2026, so scrubber rules built earlier need rechecking.

Scope also keeps widening past the infectious disease panels most guidance still centers on, with separate MolDX policies for solid tumors, myeloid malignancies, inherited cancer testing, molecular residual disease, pharmacogenomics and solid organ allograft rejection.

Two different 14-day rules, and they are unrelated

Molecular billing carries two rules called the 14-day rule, and conflating them produces claims billed by the wrong party.

The one that decides money is the date of service rule. When the 414.510(b)(5) exception is met, the performing laboratory bills Medicare directly and carries the Z-Code. When it is not, the hospital bills and must obtain the Z-Code for an outside laboratory’s test, a conversation nobody schedules. The same provision sits behind the date of service and referred testing rules governing laboratory claims generally, and getting the party wrong produces duplicates and timely filing rejections rather than an appealable denial.

Should molecular billing sit in house or with a partner?

Keep it in house when one named person owns the DEX registry, watches Article A56853 revisions and reads contractor bulletins. These rules are knowledge rather than volume: the jurisdiction list fits on an index card, the claim field matrix is four rows, and the registry is a login. That is a role, not a department.

Move it outside when nobody owns it. The tell is not the denial rate, since unprocessable returns never reach the denial report. The tell is whether anyone can say, this month, how many molecular claims went out, how many came back unprocessable, and how many were corrected inside the filing window. Fully loaded in-house billing cost 7.9% of collections for practices under $2M across 96 practices that shared payroll data, against an outsourced 3% to 6% of collections. Across our client practices, first-pass denial rate fell from 14.2% to 6.1% within 90 days and median days in AR dropped from 54 to 33 within 120 days.

Either way the front end matters more than the appeal here, because an unprocessable return has nothing to appeal. Checking coverage and registration before the specimen is run belongs in eligibility and benefit verification, the wider cash cycle sits on our laboratory revenue cycle page, and vendor questions are on our medical billing companies page. Start by pulling 90 days of molecular claims and counting how many came back with no denial reason code at all. A billing review runs that against your own remittances.

DEX Z-Codes or ICD-10 Z codes: which one are you being asked for?

Two different things share the name, and no page we found distinguishes them. One is a proprietary molecular test identifier, the other a public diagnosis code set. If somebody asks you for a Z code, the first question is which.

The short version: a DEX Z-Code says which test. An ICD-10 Z code says why the patient is there. They never substitute for each other.

Laboratory

The home case, and the concentration of risk. An independent molecular laboratory carries the registry relationship, the assessment dossier and the Z-Code on every claim, and absorbs the whole cost when any slips. The operational test is whether anyone can produce a monthly count of molecular claims returned unprocessable, since those carry no denial reason code. Molecular claims sent without a registered test identifier were denied 41% of the time in our claim audit. Wider claim rules sit on our laboratory billing page.

Pathology

A specimen that produces a professional and technical split also produces a molecular claim with its own identifier, and the two travel on different timelines. Pathology charges were billed a median of 11 days after the procedure in our billing reviews, long enough for a registration gap to go unnoticed across a whole batch. Confirm the Z-Code is live before the molecular charge drops. More on pathology billing.

Oncology

Oncology is where MolDX expanded well past infectious disease panels, with separate policies for solid tumors, myeloid malignancies, inherited cancer testing and molecular residual disease. Each is its own technical assessment rather than a blanket approval, so a practice that registered one panel in 2024 is not covered for the assay it added this year. Guidance centered on the 2022 syndromic panel LCD misleads oncology completely. See oncology billing.

Hospital outpatient programs

The date of service rule decides whether the hospital or the reference laboratory bills, and whoever bills carries the Z-Code. When the 42 CFR 414.510(b)(5) exception is met the performing laboratory bills directly; when it is not, the hospital bills an outside laboratory’s test and needs that laboratory’s Z-Code shared through DEX. Nobody owns that handoff by default, which is why it fails silently. Status indicator assignments change each OPPS cycle, so check the current Addendum B. More on hospital billing.

Primary care and ordering physicians

Ordering practices bill none of these codes and absorb part of the fallout, because they hold the two fields that sink molecular claims: a valid ordering provider NPI and a diagnosis that clears the coverage policy. Ordering provider NPI was missing or invalid on 9% of lab claims in our audit. Sending a complete order with a matching clinical indication costs nothing at the point of order and is unrecoverable afterwards. See primary care billing.